Athenex, a clinical-stage biotech developing novel therapeutics for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Buffalo, NY-based company was founded in 2003 and it plans to list on the Nasdaq under the symbol ATNX. Athenex filed confidentially on December 16, 2016. Credit Suisse, J.P. Morgan and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
